/PRNewswire/ The "Antifungal Drug Market Research Report by Infection Type, Type, Form, Therapeutic Indications, and Region - Global Forecast to 2026 -.
/PRNewswire/ The "Antifungal Drug Market Research Report by Infection Type, Type, Form, Therapeutic Indications, and Region - Global Forecast to 2026 -.
SEATTLE, May 31, 2021 (GLOBE NEWSWIRE) According to Coherent Market Insights, the India mucormycosis treatment (black fungus drug) market is estimated to be valued at US$ 9.1 million in 2021, and is expected to exhibit a CAGR of 3.5% during the forecast period (2021-2028). Key Trends and Analysis of the India mucormycosis treatment (black fungus drug) Market: Key trends in the market include increasing research and development activities, product launches and approvals, inorganic activities such as acquisitions, increasing prevalence of fungal infections, and others. Key players are engaged in manufacturing anti-fungal drugs, for the treatment of mucormycosis, which will reduce the shortage of the drugs required for the treatment of mucormycosis infection. This is expected to fuel growth of the India mucormycosis treatment (black fungus drug) market over the forecast period. For instance, on May 27, 2021, Genetic Life Sciences, a Maharashtra-based pharmaceutical manufacturing company
Black Fungus: 5 pharma cos get DCGI s nod to produce Amphotericin B
The five companies that got DCGI s nod to manufacture Amphotericin B liposomal injection are Alembic Pharmaceuticals, Emcure Pharmaceuticals, Gufic Biosciences, Lyca Pharmaceuticals, and Natco Pharma
BusinessToday.In | May 21, 2021 | Updated 11:06 IST
Amphotericin B is used in the treatment of black fungus or mucormycosis and is currently in short supply
The Drug Controller General of India (DCGI) has granted approval to five pharma companies to start manufacturing antifungal anti-fungal drug Amphotericin B liposomal injection, whose demand has increased in the wake of a surge in black fungus infections.
The five companies that got DCGI s nod are Alembic Pharmaceuticals, Emcure Pharmaceuticals, Gufic Biosciences, Lyca Pharmaceuticals, and Natco Pharma. Presently six firms - BDR Pharma, Bharat Serums and Vaccines, Mylan, Sun Pharma, Cipla, and Life Care - are producing the drug.